Since Treg has been implicated in pathogenesis and prognosis of multiple cancer types [35,36,37,38,39], it is anticipated that anti-CTLA-4 antibodies that effectively and selectively deplete Treg in tumor microenvironment would have a broad impact in cancer immunotherapy. The gene discussed is CTLA4; the disease is neoplasm.